Bilix Ltd CEO Myung Kim sat down with Proactive at the 2019 BIO Investor Forum in San Francisco.
Kim says when patients are struck with a heart attacks, 40% of patients who survive, die within 1 year. South Korean-based Bilix is developing a therapy to prevent this from happening.